BioMarin Pharmaceutical (NASDAQ:BMRN) EVP Henry Fuchs unloaded 10,000 shares of the stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $80.19, for a total transaction of $801,900.00. Following the completion of the sale, the executive vice president now directly owns 43,266 shares in the company, valued at approximately $3,469,501. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of analysts have recently weighed in on BMRN shares. Analysts at Wedbush reiterated a “hold” rating on shares of BioMarin Pharmaceutical (NASDAQ:BMRN) in a research note to investors on Friday. They now have a $88.00 price target on the stock. Separately, analysts at William Blair reiterated a “hold” rating on shares of BioMarin Pharmaceutical (NASDAQ:BMRN) in a research note to investors on Wednesday, September 18th. They now have a $88.00 price target on the stock. Finally, analysts at RBC Capital reiterated a “buy” rating on shares of BioMarin Pharmaceutical (NASDAQ:BMRN) in a research note to investors on Wednesday, September 18th. They now have a $77.00 price target on the stock.
Eight analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. BioMarin Pharmaceutical has an average rating of “Buy” and an average target price of $72.68.
Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) traded down 4.22% on Monday, hitting $73.70. The stock had a trading volume of 2,260,270 shares. BioMarin Pharmaceutical has a one year low of $36.28 and a one year high of $80.67. The stock’s 50-day moving average is $67.97 and its 200-day moving average is $63.58. The company’s market cap is $10.326 billion.
BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Thursday, July 25th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.13. The company had revenue of $136.80 million for the quarter, compared to the consensus estimate of $134.33 million. During the same quarter in the previous year, the company posted ($0.27) earnings per share. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, analysts predict that BioMarin Pharmaceutical will post $-1.15 earnings per share for the current fiscal year.
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.